Drugs / AZD2811
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03217838 | Jul 2017 → Mar 2021 | acute myeloid leukemia | AstraZeneca | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT02579226 | Oct 2015 → Feb 2020 | neoplasm | AstraZeneca | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04745689 | Feb 2021 → Jun 2022 overdue | small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04525391 | Sep 2020 → Jan 2022 | small cell lung carcinoma | Se-Hoon Lee | Terminated | No outcome recorded |
| Phase 2 | NCT03366675 | Dec 2017 → Oct 2018 | small cell lung carcinoma | Samsung Medical Center | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD2811 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04525391 ↗ |
| Action | Inhibit | “AZD2811 is an AURKB inhibitor” PMID 41933194 ↗ Apr 2026 |
| Route | Intravenous | “AZD2811 was administered in 12 dose-escalation cohorts (2-h intravenous infusion; 15‒600 mg; 21-/28-day cycles)” PMID 36871042 ↗ Mar 2023 |
| Target | AURKB | “AZD2811 is an AURKB inhibitor” PMID 41933194 ↗ Apr 2026 |